Table 1.
Baseline Characteristics and the Comparison of Clinical Characteristics between the Iliac and SFA Lesions.
| Variables | All patients n=60 | Iliac lesions n=30 | SFA lesions n=30 | p value | ||||
|---|---|---|---|---|---|---|---|---|
| Age (years old) | 73±8 | 72±7 | 74±8 | 0.315 | ||||
| Men / Women | 52 / 8 | 24 / 6 | 28 / 2 | 0.121 | ||||
| BMI (kg/m2) | 23.1±3.6 | 23.6±4.0 | 22.7±3.2 | 0.390 | ||||
| Claudication (Rutherford 2 or 3), n (%) | 49 (82) | 25 (83) | 24 (80) | 0.739 | ||||
| Critical limb ischemia (Rutherford 4-6), n (%) | 11 (18) | 5 (17) | 6 (20) | 0.739 | ||||
| pre-ABI | 0.57±0.22 | 0.57±0.24 | 0.57±0.21 | 0.991 | ||||
| post-ABI | 0.90±0.15 | 0.90±0.16 | 0.90±0.14 | 0.852 | ||||
| Hypertension, n (%) | 49 (82) | 24 (80) | 25 (83) | 0.739 | ||||
| Diabetes mellitus, n (%) | 20 (33) | 10 (33) | 10 (33) | 1.000 | ||||
| Dyslipidemia, n (%) | 37 (62) | 19 (63) | 18 (60) | 0.791 | ||||
| CKD, n (%) | 26 (43) | 9 (30) | 17 (57) | 0.036 | ||||
| Hemodialysis, n (%) | 12 (20) | 3 (10) | 9 (30) | 0.049 | ||||
| Previous IHD, n (%) | 23 (38) | 11 (37) | 12 (40) | 0.791 | ||||
| Previous stroke, n (%) | 15 (25) | 7 (23) | 8 (27) | 0.766 | ||||
| Uncontrolled hypertension, n (%) | 6 (10) | 3 (10) | 3 (10) | 1.000 | ||||
| Smoking, n (%) | 55 (92) | 27 (90) | 28 (93) | 0.639 | ||||
| Number of antiplatelet agents | 1.9±0.3 | 1.9±0.4 | 1.9±0.3 | 0.703 | ||||
| Number of antihypertensive agents | 1.8±1.0 | 1.7±1.0 | 1.8±0.9 | 0.502 | ||||
| Blood examination | ||||||||
| eGFR (mL/min/1.73 m2) | 56.7±33.0 | 63.9±29.2 | 49.5±35.5 | 0.098 | ||||
| Triglycerides (mg/dL) | 132.9±79.8 | 143.2±88.1 | 122.5±70.5 | 0.327 | ||||
| LDL-C (mg/dL) | 93.7±30.0 | 97.2±25.2 | 90.1±34.1 | 0.369 | ||||
| HDL-C (mg/dL) | 51.4±16.9 | 49.2±17.4 | 53.5±16.4 | 0.339 | ||||
| HbA1c (%) | 6.3±0.8 | 6.3±0.7 | 6.3±1.0 | 0.913 | ||||
| BNP (pg/mL) | 44.4 (11.6 - 129.9) | 42.0 (9.9 - 74.2) | 53.5 (13.7 -176.5) | 0.390 | ||||
| hs-CRP (mg/dL) | 0.11 (0.05 - 0.21) | 0.11 (0.03 - 0.20) | 0.11 (0.06 - 0.30) | 0.102 | ||||
| Medications | ||||||||
| ACEIs and/or ARBs, n (%) | 47 (78) | 23 (77) | 24 (80) | 0.754 | ||||
| CCBs, n (%) | 40 (67) | 18 (60) | 22 (73) | 0.272 | ||||
| β-blockers, n (%) | 18 (30) | 9 (30) | 9 (30) | 1.000 | ||||
| Statins, n (%) | 40 (67) | 18 (60) | 22 (73) | 0.272 | ||||
| Nitrates, n (%) | 9 (15) | 3 (10) | 6 (20) | 0.274 | ||||
| Aldosterone blockers, n (%) | 7 (12) | 1 (3) | 6 (20) | 0.035 | ||||
| Aspirin, n (%) | 41 (68) | 21 (70) | 20 (67) | 0.781 | ||||
| Clopidogrel, n (%) | 55 (92) | 27 (90) | 28 (93) | 0.639 | ||||
| Cilostazol, n (%) | 15 (25) | 5 (17) | 10 (33) | 0.133 |
Data are expressed as mean±SD, number (percentage), or median (interquartile range).
ABI: ankle-brachial arterial pressure index, ACEIs: angiotensin-converting enzyme inhibitors, ARBs: angiotensin II receptor blockers, BMI: body mass index, BNP: B-type natriuretic peptide, CCBs: calcium-channel blockers, CKD: chronic kidney disease, eGFR: estimated glomerular filtration rate, HbA1c: hemoglobin A1c, HDL-C: high-density lipoprotein cholesterol, hs-CRP: high-sensitivity C-reactive protein, IHD: ischemic heart disease, LDL-C: low-density lipoprotein cholesterol, SFA: superficial femoral artery